Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05011058 |
|---|---|
| Brief Title: | An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) |
| First Submitted : | August 2, 2021 |
| First Submitted that Met QC Criteria : | August 11, 2021 |
| First Posted : | August 18, 2021 |
| Last Update Submitted that Met QC Criteria : | April 30, 2024 |
| Last Update Posted : | May 1, 2024 |